CN102462840A - 乙肝治疗性疫苗 - Google Patents
乙肝治疗性疫苗 Download PDFInfo
- Publication number
- CN102462840A CN102462840A CN2010105399363A CN201010539936A CN102462840A CN 102462840 A CN102462840 A CN 102462840A CN 2010105399363 A CN2010105399363 A CN 2010105399363A CN 201010539936 A CN201010539936 A CN 201010539936A CN 102462840 A CN102462840 A CN 102462840A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- sequence
- albumen
- group
- surface antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title claims abstract description 21
- 229940124736 hepatitis-B vaccine Drugs 0.000 title claims abstract description 21
- 230000001225 therapeutic effect Effects 0.000 title abstract description 9
- 239000013612 plasmid Substances 0.000 claims abstract description 74
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 239000000427 antigen Substances 0.000 claims abstract description 44
- 102000036639 antigens Human genes 0.000 claims abstract description 44
- 108091007433 antigens Proteins 0.000 claims abstract description 44
- 210000004185 liver Anatomy 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 44
- 239000003480 eluent Substances 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 25
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 229920002684 Sepharose Polymers 0.000 claims description 15
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 238000004255 ion exchange chromatography Methods 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 210000002826 placenta Anatomy 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 230000002490 cerebral effect Effects 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000002313 intestinal cancer Diseases 0.000 claims description 5
- 201000010174 renal carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000005457 optimization Methods 0.000 claims description 2
- 101710132601 Capsid protein Proteins 0.000 abstract description 55
- 102000004169 proteins and genes Human genes 0.000 abstract description 23
- 241000700605 Viruses Species 0.000 abstract description 5
- 241000700721 Hepatitis B virus Species 0.000 abstract description 4
- 230000010076 replication Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 description 32
- 230000003053 immunization Effects 0.000 description 31
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 20
- 108010082126 Alanine transaminase Proteins 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 230000036039 immunity Effects 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 101710137302 Surface antigen S Proteins 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 7
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 231100000284 endotoxic Toxicity 0.000 description 4
- 230000002346 endotoxic effect Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 229920004929 Triton X-114 Polymers 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002777 nucleoside Chemical class 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000235061 Pichia sp. Species 0.000 description 1
- 108700011066 PreScission Protease Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960003205 adefovir dipivoxil Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical class CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010539936.3A CN102462840B (zh) | 2010-11-09 | 2010-11-09 | 乙肝治疗性疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010539936.3A CN102462840B (zh) | 2010-11-09 | 2010-11-09 | 乙肝治疗性疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102462840A true CN102462840A (zh) | 2012-05-23 |
CN102462840B CN102462840B (zh) | 2014-03-19 |
Family
ID=46067148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010539936.3A Active CN102462840B (zh) | 2010-11-09 | 2010-11-09 | 乙肝治疗性疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102462840B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104043120A (zh) * | 2013-03-13 | 2014-09-17 | 江苏先声药业有限公司 | 乙型肝炎疫苗 |
CN104873969A (zh) * | 2015-04-16 | 2015-09-02 | 江苏赛锘威生物医药有限公司 | 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗 |
CN105194668A (zh) * | 2015-10-22 | 2015-12-30 | 中国科学院微生物研究所 | 一种gp96蛋白和PD1抗体的偶联物的制备方法及其应用 |
CN105727279A (zh) * | 2016-03-25 | 2016-07-06 | 汪和睦 | 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗 |
CN106928372A (zh) * | 2016-12-30 | 2017-07-07 | 北京大学深圳研究生院 | 乙肝重组抗原及其表达基因、构建方法、病毒样颗粒及其制备方法、应用与疫苗 |
CN107325176A (zh) * | 2017-06-16 | 2017-11-07 | 神威药业集团有限公司 | 源于血红蛋白的免疫活性人胎盘多肽 |
CN110172080A (zh) * | 2019-05-16 | 2019-08-27 | 南京大户生物科技有限公司 | 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1316431A (zh) * | 2000-08-11 | 2001-10-10 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
CN1718243A (zh) * | 2004-07-07 | 2006-01-11 | 中国科学院微生物研究所 | 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用 |
-
2010
- 2010-11-09 CN CN201010539936.3A patent/CN102462840B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1316431A (zh) * | 2000-08-11 | 2001-10-10 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
CN1718243A (zh) * | 2004-07-07 | 2006-01-11 | 中国科学院微生物研究所 | 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用 |
Non-Patent Citations (4)
Title |
---|
HONG-TAO LI ET AL: "Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice", 《WORLD JOURNAL OF GASTROENTEROLOGY》 * |
SONG-DONG MENG ET AL: "Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides", 《JOURNAL OF IMMUNOLOGICAL METHODS》 * |
WANG S,ET AL: "Heat shock protein gp96 enhances humoral and T cell responses,decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice", 《VACCINE》 * |
王彦中等: "热休克蛋白HSP70 和gp96增强乙肝DNA疫苗的细胞", 《生物工程学报》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104043120A (zh) * | 2013-03-13 | 2014-09-17 | 江苏先声药业有限公司 | 乙型肝炎疫苗 |
EP2974740A4 (en) * | 2013-03-13 | 2016-08-24 | Jiangsu Theravac Bio Pharmaceutical Co Ltd | VACCINE AGAINST HEPATITIS B |
CN104043120B (zh) * | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
US9878035B2 (en) | 2013-03-13 | 2018-01-30 | Jiangsu Theravac Bio-Pharmaceutical Co., Ltd. | Hepatitis B vaccine |
CN104873969A (zh) * | 2015-04-16 | 2015-09-02 | 江苏赛锘威生物医药有限公司 | 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗 |
CN104873969B (zh) * | 2015-04-16 | 2018-06-19 | 南京赛威信生物医药有限公司 | 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗 |
CN105194668A (zh) * | 2015-10-22 | 2015-12-30 | 中国科学院微生物研究所 | 一种gp96蛋白和PD1抗体的偶联物的制备方法及其应用 |
CN105194668B (zh) * | 2015-10-22 | 2019-03-26 | 中国科学院微生物研究所 | 一种gp96蛋白和PD1抗体的偶联物的制备方法及其应用 |
CN105727279A (zh) * | 2016-03-25 | 2016-07-06 | 汪和睦 | 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗 |
CN106928372A (zh) * | 2016-12-30 | 2017-07-07 | 北京大学深圳研究生院 | 乙肝重组抗原及其表达基因、构建方法、病毒样颗粒及其制备方法、应用与疫苗 |
CN107325176A (zh) * | 2017-06-16 | 2017-11-07 | 神威药业集团有限公司 | 源于血红蛋白的免疫活性人胎盘多肽 |
CN110172080A (zh) * | 2019-05-16 | 2019-08-27 | 南京大户生物科技有限公司 | 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102462840B (zh) | 2014-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102462840B (zh) | 乙肝治疗性疫苗 | |
JP6109989B2 (ja) | 慢性b型肝炎感染症のための酵母系治療薬 | |
Gong et al. | Peptide-based vaccines for tuberculosis | |
CA2950863C (en) | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection | |
CN103732250A (zh) | 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法 | |
Cui et al. | A novel tetrameric gp3501–470 as a potential Epstein–Barr virus vaccine | |
Li et al. | A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine | |
CN101361969B (zh) | 一种治疗性乙肝疫苗及其制备方法和用途 | |
Yang et al. | Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy | |
CN104815325B (zh) | 诱导改善的免疫反应的疫苗 | |
CN104341506A (zh) | 一种重组融合蛋白及其用途 | |
CN105194668A (zh) | 一种gp96蛋白和PD1抗体的偶联物的制备方法及其应用 | |
CN102462841A (zh) | 一种促进gp96蛋白的免疫活性的方法及其应用 | |
CN102199217B (zh) | 乙型肝炎病毒多表位融合蛋白及其制备方法和应用 | |
Shi et al. | Therapeutic polypeptides based on HBcAg18-27 CTL epitope can induce antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice | |
CN103239717B (zh) | 治疗慢性乙型肝炎的复制子dna疫苗 | |
Wang et al. | HBcAg18–27 epitope fused to HIV-Tat49–57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice | |
Song et al. | Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo | |
CN101618211A (zh) | 一种乙肝多肽疫苗及其应用 | |
CN100535002C (zh) | 重组结核杆菌抗原多表位肽及其构建方法与用途 | |
RU2806556C1 (ru) | Искусственный ген, кодирующий белок-иммуноген BSI-COV, рекомбинантная плазмидная ДНК pBSI-COV, обеспечивающая экспрессию целевого гена, и искусственный полиэпитопный белок-иммуноген BSI-COV, содержащий эпитопы антигенов вируса SARS-CoV-2 и индуцирующий SARS-CoV-2-специфический T-клеточный иммунитет | |
Corradin | Antigen processing and presentation | |
Nam et al. | Modulation of immune response induced by co-administration of DNA vaccine encoding HBV surface antigen and HCV envelope antigen in BALB/c mice | |
WO2015130488A2 (en) | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection | |
Wijayadikusumah | An evaluation of charged Pam2Cys-based lipopeptides as novel adjuvants for subunit-based vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NANTONG BIOLOGICAL SCIENCE PARK DEVELOPMENT INVEST Free format text: FORMER OWNER: MICROBIOLOGY INST., CHINESE ACADEMY OF SCIENCES Effective date: 20130924 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100101 CHAOYANG, BEIJING TO: 226002 NANTONG, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130924 Address after: 226002, No. 118, city road, Gangzha District, Jiangsu, Nantong Applicant after: INSTITUTE OF MICROBIOLOGY CHINESE ACADEMY OF SCIENCES Address before: 100101 Institute of Microbiology, Chinese Academy of Sciences, No. 1, West Beichen Road, Chaoyang District, Beijing, Applicant before: Institute of Microbiology, Chinese Academy of Sciences |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160718 Address after: 100101 Beichen West Road, Beijing, No. 1 hospital, No. 3, No. Patentee after: Institute of Microbiology, Chinese Academy of Sciences Address before: 226002, No. 118, city road, Gangzha District, Jiangsu, Nantong Patentee before: INSTITUTE OF MICROBIOLOGY CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200409 Address after: 101599 No.1, Qiangyun Road, Miyun Economic Development Zone, Beijing Patentee after: Beijing Sino pharmaceutical Limited by Share Ltd Address before: 100101 No. 1, West Beichen Road, Beijing, Chaoyang District, 3 Patentee before: INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200506 Address after: 100124 floor 3, unit 2, No.26 Xidian village, Gaobeidian Township, Chaoyang District, Beijing Patentee after: BEIJING REXIU BIOTECHNOLOGY Co.,Ltd. Address before: 101599 No.1, Qiangyun Road, Miyun Economic Development Zone, Beijing Patentee before: Beijing Sino pharmaceutical Limited by Share Ltd |